CONCLUSIONS: Long-term follow up of CIE mice revealed two differential phenotypes of neurologic impairment mimicking two forms of MS in humans: relapsing-remissive MS and chronic inflammatory type of MS. Mice in RELAP group had a decreased response to M3 agonists suggesting that anti-muscarinic drugs may have limited effects on neurogenic bladder in this type of MS.
INTRODUCTION AND OBJECTIVES: Lower urinary tract symptoms (LUTS) are common and poorly understood; treatment is often ineffective. Failure of neural control of bladder function likely contributes to LUTS symptoms in many patients. Prior studies have shown that the pontine micturition center (PMC) directly controls voiding. Within the PMC corticotropin releasing hormone neurons (PMC CRH ) project axons directly to spinal sacral cord nuclei that control bladder contraction. Here we show that PMC CRH neurons are critical for voiding, and identify neurons, particularly in the ventrolateral periaqueductal gray (PAG VL ) which directly modulate PMC CRH and alter voiding.
METHODS: We inject adeno-associated viruses expressing proteins in a Cre-dependent fashion into anatomically defined regions of mice expressing Cre recombinase in specific neural types, to cause highly selective expression of these probes in target neuron populations. We monitor conscious voiding with micturition video thermography (MVT), and CMG under anesthesia while monitoring/ stimulating specific neuron groups.
RESULTS: Stimulating PMC CRH neurons using designer receptors exclusively activated by designer drugs (DREADDs) produces urinary frequency in awake mice and on anesthetized CMG. Also, ablating PMC CRH neurons by selective expression of diphtheria toxin A disrupts normal voiding and the normal CMG voiding reflex. To identify neurons which provide input to PMC CRH , we used modified rabies virus and cholera toxin B labeling of PMC CRH and confirmed our results with viral anterograde tracing. Afferents to PMC CRH are located in PAG VL , the preoptic area, the lateral hypothalamic area, and other sites. Because sacral afferents sensing bladder filling project to PAG VL we determined the impact of stimulating Glutamatergic or GABA-ergic neurons (PAG VL -GLUT or PAG VL GABA ) in this region. Chemogenetic or optogenetic stimulation of PAG VL GLUT neurons leads to voiding and detrusor contraction. By contrast, chemogenetic or optogenetic activation of PAG VL GABA inhibits voiding and delays detrusor contraction on CMG.
CONCLUSIONS: 1. PMC CRH are driver neurons for detrusor contraction/voiding. 2. PAG VL GLUT project to PMC CRH , and when fired drive voiding/detrusor contraction. 3. PAG VL GABA project to PMC CRH and inhibit voiding/detrusor contraction. PAG VL , which receives bladderbased sacral afferents, likely controls bladder filling, and is a potential target in efforts to control urge incontinence and urgency symptoms of LUTS. often ineffective. Failure of neural control of bladder function likely contributes to LUTS symptoms in many patients. Mice are continent and serve as excellent models of LUTS, in part because they can be manipulated genetically. To relate what is learned in mice to humans, we have developed functional MRI methods for mice which mirror those in humans. Such methods will allow us to compare directly the activation patterns of mouse and human brains during bladder filling and voiding, in normal and disease states.
METHODS: Mice are anesthetized with urethane and a catheter is implanted in the bladder dome. Blood Oxygen Level Detection Magnetic Resonance Imaging (BOLD-MRI) is carried out in a Bruker 9.4T magnet with a 4 element mouse brain phased array coil. A series of 2D multislice gradient echo-planar images are acquired every 2s, while the mouse undergoes cystometry. 25 slices are acquired with slices of 500mm, interslice distance 600mm and in-plane resolution of 250mm. Imaging occurs over a 45 minute time frame during which the mouse undergoes 10-15 voiding cycles (CMG). Data are analyzed with Statistical Parameter Mapping (SPM12) software using mouse brain adaptations. Linear modeling proceeds in 2 stages; first by providing a statistical map of the brain of individual animals and second by combining results across all animals in a group.
RESULTS: Preliminary results on female C57BL6/J (n ¼5) with a fixed effects analysis identified candidate regions across the brain with clear activation in the right Pontine Micturition Center (PMC) observed, which was confirmed by a region based random effects analysis. Negative contrast identified more extensive regions such as the periaqueductal gray and inferior colliculus with an indication that these regions are 00 switched off 00 during the transition to voiding.
CONCLUSIONS: Although technically challenging due to the small size, BOLD-MRI on mice is feasible and reveals regions of brain activation related to voiding cycles. Development of this technique along with fine mapping of brain circuits related to voiding will help define mechanisms of LUTS in mouse models that should be translatable to human disease. As such, dLPP>40, despite clean intermittent catheterization (CIC) and anticholinergics, often mandates augmentation or diversion. While we recommend augmentation cystoplasty or diversion to appropriate patients, many elect for non-surgical management. Non-surgical management consists of rigorous urodynamic (UDS) and renal ultrasound (RUS) follow-up, paired with adjustments to CIC routine to keep bladder volumes below that volume at which dLPP>40, adjustments to anticholinergics, and intradetrusor botulinum toxin Type A (BTX). We describe the renal function outcomes of nonsurgical management of adults with poorly compliant (dLPP>40) NGB.
METHODS: We retrospectively reviewed the charts of all patients at our Gillette Lifetime adult congenital urology clinic undergoing UDS from January 2011 to June 2016. Patients with dLPP>40 who opted for non-surgical management were included; this study was noted as their 00 index UDS 00 for calculation of follow-up. The primary endpoint was deterioration of renal function as evidenced by change in chronic kidney disease (CKD) stage, progression to CKD-III, or new/worsening hydronephrosis.
RESULTS: Of 210 patients who underwent UDS, 45 had dLPP>40. After exclusions for incomplete data (n¼7) or augmentation cystoplasty (n¼11), 27 were the subject of study. 15/27 (56%) were women and all 27 were Caucasian. Median age was 29 years (IQR 25, e1150
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